KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2016 - 2025)

Alnylam Pharmaceuticals' Interest & Investment Income history spans 16 years, with the latest figure at $26.6 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 14.15% year-over-year to $26.6 million; the TTM value through Dec 2025 reached $111.5 million, down 8.63%, while the annual FY2025 figure was $111.5 million, 8.63% down from the prior year.
  • Interest & Investment Income reached $26.6 million in Q4 2025 per ALNY's latest filing, down from $28.7 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $32.1 million in Q3 2024 to a low of $225000.0 in Q3 2021.
  • Average Interest & Investment Income over 5 years is $17.8 million, with a median of $23.2 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: crashed 91.79% in 2021, then skyrocketed 3375.56% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $495000.0 in 2021, then skyrocketed by 2743.84% to $14.1 million in 2022, then skyrocketed by 116.0% to $30.4 million in 2023, then increased by 2.02% to $31.0 million in 2024, then fell by 14.15% to $26.6 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Interest & Investment Income are $26.6 million (Q4 2025), $28.7 million (Q3 2025), and $27.5 million (Q2 2025).